1 ELECTRONIC SUPPLEMENTARY MATERIAL FIGURE LEGENDS

2

3	Supplementary Figure S1. Functionality and efficiency of the MOs used.
4	(a-a') EGFP expression is observed after injection of 100 pg of <i>tbx5a-EGFP</i> mRNA into
5	1-cell stage embryos. (b-b') Co-injection with <i>tbx5a</i> MO caused the disappearance of
6	EGFP signal. (c-c') Injection of 100 pg of <i>tbx5b-EGFP</i> mRNA caused detectable
7	expression of EGFP in 24hpf embryos. (d-d') Chimeric <i>tbx5b</i> mRNA-driven EGFP
8	expression is abolished by co-injection with the $tbx5b(UTR)$ MO. (e) RT-PCR from RNA
9	extracted from injected embryos with a <i>control</i> MO or a <i>tbx5b(SP)</i> MO showing the
10	expected 215 bp (spliced) band in control embryos in comparison to the 791bp
11	(unspliced) bands in <i>tbx5b(SP)</i> MO injected embryos.
12	
13	Supplementary Figure S2. <i>efnb2a</i> expression analyses.
14	(a) Quantification of the total extent of <i>efnb2a</i> expression by setting an imaginary hinge
15	in the centre of the lens. (b) Dorso-nasal and (c) dorso-temporal angles measured by
16	setting the dorsal-most point as the point lying dorsal to the ventrally-located choroid
17	fissure. A Kruskal-Wallis test was used to determine statistical differences among
18	experimental conditions (*P<0.05, **P<0.001).



tbx5a-GFP RNA



tbx5a-GFP RNA + tbx5a MO





Pi-Roig, electronic supplementary material Figure S1

